In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on T2 Biosystems (TTOO). The company’s shares closed last Monday at $2.61.
Chen said:
“We currently do not have a price target on TTOO shares. Our prior price target was derived from an estimated market value of the firm at $557M, which included a discounted cash flow analysis based asset value of $600M for T2Dx instrument and test panels, with a 15% discount rate and 0% terminal growth rate, excluding $42M outstanding debt.”
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -20.2% and a 34.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.
T2 Biosystems has an analyst consensus of Hold, with a price target consensus of $1.95, representing a 3.2% upside. In a report released yesterday, JonesTrading also reiterated a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.70 and a one-year low of $0.52. Currently, T2 Biosystems has an average volume of 1.67M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology.
